References
- Assurance Maladie. (n. d.). Le score EPICES : l’indicateur de précarité des centres d’examens de santé de l’Assurance Maladie. http://www.departement-information-medicale.com/wp-content/uploads/2009/05/re_precarite.pdf
- Bezabhe, W., Chalmers, L., Bereznicki, L., & Peterson, G. (2016). Adherence to antiretroviral therapy and virologic failure. Medicine, 95(15), e3361. https://doi.org/10.1097/MD.0000000000003361
- Delaugerre, C., Gallien, S., Flandre, P., Mathez, D., Amarsy, R., Ferret, S., Timsit, J., Molina, J.-M., & de Truchis, P. (2012). Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PloS One, 7(5), e36673. https://doi.org/10.1371/journal.pone.0036673
- Fletcher, C. V., Staskus, K., Wietgrefe, S. W., Rothenberger, M., Reilly, C., Chipman, J. G., Beilman, G. J., Khoruts, A., Thorkelson, A., Schmidt, T. E., Anderson, J., Perkey, K., Stevenson, M., Perelson, A. S., Douek, D. C., Haase, A. T., & Schacker, T. W. (2014). Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proceedings of the National Academy of Sciences, 111(6), 2307–2312. https://doi.org/10.1073/pnas.1318249111
- Gallien, S., Delaugerre, C., Charreau, I., Braun, J., Boulet, T., Barrail-Tran, A., de Castro, N., Molina, J.-M., & Kuritzkes, D. R. (2011). Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS (London, England), 25(5), 665–669. https://doi.org/10.1097/QAD.0b013e3283445834
- Grossberg, R., & Gross, R. (2007). Use of pharmacy refill data as a measure of antiretroviral adherence. Current HIV/AIDS Reports, 4(4), 187–191. https://doi.org/10.1007/s11904-007-0027-4
- Joya, C., Won, S. H., Schofield, C., Lalani, T., Maves, R. C., Kronmann, K., Deiss, R., Okulicz, J., Agan, B. K., & Ganesan, A. (n. d.). Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clinical Infectious Diseases, https://doi.org/10.1093/cid/ciz129
- Konstantopoulos, C., Ribaudo, H., Ragland, K., Bangsberg, D. R., & Li, J. Z. (2015). Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infectious Diseases, 2(1), ofu119. https://doi.org/10.1093/ofid/ofu119
- Labbe, E., Blanquet, M., Gerbaud, L., Poirier, G., Sass, C., Vendittelli, F., & Moulin, J.-J. (2015). A new reliable index to measure individual deprivation : The EPICES score. European Journal of Public Health, 25(4), 604–609. https://doi.org/10.1093/eurpub/cku231
- Laprise, C., de Pokomandy, A., Baril, J.-G., Dufresne, S., & Trottier, H. (2013). Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients : results from 12 years of observation. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 57(10), 1489–1496. https://doi.org/10.1093/cid/cit529
- Leierer, G., Grabmeier-Pfistershammer, K., Steuer, A., Geit, M., Sarcletti, M., Haas, B., Kanatschnig, M., Rappold, M., Zangerle, R., Ledergerber, B., Taylor, N., & Austrian HIV Cohort Study Group (2015). Factors associated with Low-level viraemia and virological failure : results from the Austrian HIV cohort study. PloS One, 10(11), e0142923. https://doi.org/10.1371/journal.pone.0142923
- Li, J. Z., Gallien, S., Do, T. D., Martin, J. N., Deeks, S., Kuritzkes, D. R., & Hatano, H. (2012). Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrobial Agents and Chemotherapy, 56(11), 5998–6000. https://doi.org/10.1128/AAC.01217-12
- Maggiolo, F., Di Filippo, E., Comi, L., Callegaro, A., Colombo, G. L., Di Matteo, S., Valsecchi, D., & Rizzi, M. (2017). Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. Pragmatic and Observational Research, 8, 91–97. https://doi.org/10.2147/POR.S127974
- Maldarelli, F., Palmer, S., King, M. S., Wiegand, A., Polis, M. A., Mican, J., Kovacs, J. A., Davey, R. T., Rock-Kress, D., Dewar, R., Liu, S., Metcalf, J. A., Rehm, C., Brun, S. C., Hanna, G. J., Kempf, D. J., Coffin, J. M., & Mellors, J. W. (2007). ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogens, 3(4), e46. https://doi.org/10.1371/journal.ppat.0030046
- Orrell, C., Cohen, K., Leisegang, R., Bangsberg, D. R., Wood, R., & Maartens, G. (2017). Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting : which best predicts virological and resistance outcomes? AIDS Research and Therapy, 14(1), 20. https://doi.org/10.1186/s12981-017-0138-y
- Raho-Moussa, M., Guiguet, M., Michaud, C., Honoré, P., Palacios, C., Boué, F., Azghay, M., Kansau, I., Chambrin, V., Kandel, T., Favier, M., Miekoutima, E., Sayre, N., Pignon, C., Shoai, M., Bouchaud, O., & Abgrall, S. (2019). Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France. PloS One, 14(3), e0213019. https://doi.org/10.1371/journal.pone.0213019
- Ryscavage, P., Kelly, S., Li, J. Z., Harrigan, P. R., & Taiwo, B. (2014). Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrobial Agents and Chemotherapy, 58(7), 3585–3598. https://doi.org/10.1128/AAC.00076-14
- Sass, C., Guéguen, R., Moulin, J. J., Abric, L., Dauphinot, V., Dupré, C., Giordanella, J. P., Girard, F., Guenot, C., Labbe, E., La Rosa, E., Magnier, P., Martin, E., Royer, B., Rubirola, M., & Gerbaud, L. (2006). [Comparison of the individual deprivation index of the French health Examination Centres and the administrative definition of deprivation]. Sante Publique (Vandoeuvre-Les-Nancy, France), 18(4), 513–522. https://doi.org/10.3917/spub.064.0513
- Taiwo, B., Gallien, S., Aga, E., Ribaudo, H., Haubrich, R., Kuritzkes, D. R., & Eron, J. J. (2011). Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. The Journal of Infectious Diseases, 204(4), 515–520. https://doi.org/10.1093/infdis/jir353